Company at the forefront of developing personalised treatments against invasive cancer has raised 15m euros to conduct clinical trials
Oncomatryx has announced the beginning of a new phase in the development of its tumour microenvironment – targeted antibody drug conjugates (ADCs).
Phase 1 clinical trials in patients suffering metastatic solid tumours will be launched in Europe and USA in the second quarter of 2022.
